- Introducing subcutaneous infusion of a novel formulation of Furosemide
- A new chapter for one of the most important cardiovascular drugs of our time
- Reducing the volume of administration for improved cost-efficiency
Novel formulations are required for subcutaneous delivery. Furosemide is poorly soluble at neutral pH. Furosemide Injection USP, the product which has been used for over 50 years for intravenous administration, has a pH of around 9.0. This is too alkaline for subcutaneous delivery and may case a stinging/burning sensation and skin irritation. A novel higher concentration formulation with a neutral pH is under development by SQ Innovation The higher concentration allows for use of standard 3 mL cartridges and the smaller patch pumps that were originally developed for insulin delivery.
Pieter Muntendam, President and CEO, SQ Innovation AG